ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 62 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,846,884 | -19.7% | 540,722 | +12.9% | 0.00% | -33.3% |
| Q2 2023 | $13,507,033 | +84.0% | 478,803 | +12.2% | 0.00% | +200.0% |
| Q1 2023 | $7,342,180 | -13.2% | 426,871 | +1.6% | 0.00% | -50.0% |
| Q4 2022 | $8,459,686 | -6.3% | 420,044 | +0.7% | 0.00% | 0.0% |
| Q3 2022 | $9,033,000 | -14.0% | 417,042 | +11.5% | 0.00% | 0.0% |
| Q2 2022 | $10,506,000 | -32.9% | 373,900 | +10.2% | 0.00% | -33.3% |
| Q1 2022 | $15,652,000 | -46.8% | 339,231 | -3.0% | 0.00% | -40.0% |
| Q4 2021 | $29,401,000 | +26.7% | 349,765 | +0.4% | 0.01% | +25.0% |
| Q3 2021 | $23,213,000 | +42.0% | 348,332 | +13.3% | 0.00% | +33.3% |
| Q2 2021 | $16,351,000 | +33.0% | 307,330 | +8.5% | 0.00% | +50.0% |
| Q1 2021 | $12,293,000 | -16.2% | 283,323 | +0.3% | 0.00% | -33.3% |
| Q4 2020 | $14,670,000 | +211.9% | 282,442 | +96.3% | 0.00% | +200.0% |
| Q3 2020 | $4,704,000 | -26.1% | 143,892 | +8.6% | 0.00% | -50.0% |
| Q2 2020 | $6,364,000 | – | 132,536 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |